{"id":88659,"date":"2022-12-15T00:33:35","date_gmt":"2022-12-15T06:33:35","guid":{"rendered":"https:\/\/milesfortis.com\/?p=88659"},"modified":"2022-12-15T00:34:22","modified_gmt":"2022-12-15T06:34:22","slug":"88659","status":"publish","type":"post","link":"https:\/\/milesfortis.com\/?p=88659","title":{"rendered":""},"content":{"rendered":"

Moderna should have told the FDA and CDC about the bone problems in rats, and then those bureaucraps should have told the public.
\nThis is called allowing people to make informed decisions about their bodies,\u00a0 which is a very important issue for many people.
\nOf course, when I heard that the mRNA vax was going to be allowed for ’emergency use’ before<\/em> the long term study for bad effects was even started, I decided to pass taking something that had never been authorized for humans before. Of course everyone who did get the vaxx is part of that long term effect test.<\/p>\n

FDA Records Show Significant Number of mRNA Test Rats Born with Skeletal Deformations<\/a><\/p>\n

(Washington, DC)<\/b>\u00a0\u2013 Judicial Watch announced today that it received\u00a0699 pages<\/span><\/a>\u00a0of records from the Department of Health and Human Services (HHS) regarding data Moderna submitted to the Food and Drug Administration (FDA) on its mRNA COVID-19 vaccine, which indicate\u00a0<\/a>a \u201cstatistically significant\u201d number of rats were born with skeletal deformations after their mothers were injected with the vaccine. The documents also reveal Moderna elected not to conduct a number of standard pharmacological studies on the laboratory test animals.<\/strong><\/p>\n

Judicial Watch obtained the records through a September 2021 Freedom of Information Act (FOIA)\u00a0lawsuit<\/span><\/a>\u00a0filed after the FDA, the Centers for Disease Control and Prevention (CDC) and the National Institute for Allergy and Infectious Disease (NIAID) failed to respond to a June 2021, FOIA request biodistribution studies and related data for the Pfizer, Moderna and Johnson& Johnson COVID vaccines (Judicial Watch v. U.S. Department of Health and Human Services<\/span><\/i><\/a>\u00a0<\/i>(No. 1:21-cv-02418)).<\/p>\n

The records include a \u201cNonclinical Overview<\/span><\/a>\u201d prepared by Moderna and submitted to the FDA for approval of its vaccine revealing that a number of rats were born with skeletal deformations, known as \u201cwavy ribs\u201d and \u201crib nodules,\u201d to mothers injected with the mRNA vaccine. The study dismissed the anomalies as \u201cnot considered adverse:\u201d<\/p>\n

mRNA-1273-related variations in skeletal examination included statistically significant increases in the number of F1 rats with 1 or more wavy ribs and 1 or more rib nodules. Wavy ribs appeared in 6 fetuses and 4 litters with a fetal prevalence of 4.03% and a litter prevalence of 18.2%. Rib nodules appeared in 5 of those 6 fetuses. Skeletal variations are structural changes that do not impact development or function of a developing embryo, are considered reversible, and often correlate with maternal toxicity and\/or lack of other indicators of developmental toxicity (Carney and Kimmel 2007). Maternal toxicity in the form of clinical observations was observed for 5 days following the last dose (GD 13), correlating with the most sensitive period for rib development in rats (GDs 14 to 17). Furthermore, there were no other indicators of mRNA-1273-related developmental toxicity observed, including delayed ossification; therefore, these common skeletal variations were not considered adverse.<\/p>\n

(Non-adverse deformations receive a different perspective in the July 2009\u00a0Environmental Research<\/i>article, \u201cDose\u2013response relationships of rat fetal skeleton variations: Relevance for risk assessment<\/span><\/a>:\u201d<\/span><\/p>\n

(Whether or not a substance-induced increase in the incidence of fetal skeleton variations should be taken into account for human risk assessment is a long-standing controversial issue. It has been argued that chemical-produced increases in variations are not to be considered for risk assessment because they are \u201cunlikely to adversely affect survival or health.\u201d The counter argument is that even not being overtly adverse and conveying no apparent selective disadvantage, a treatment-induced increase in the occurrence of variations means that the chemical agent has the potential to perturb skeleton development. According to this view, under a different condition of exposure, or in another species, this perturbation of normal bone formation may give rise to a different and more severe outcome.))<\/p>\n

A \u201cPharmacokinetics Written Summary<\/span><\/a>\u201d marked \u201cConfidential,\u201d indicates that the information it contains is related to the mRNA-1273 (Moderna vaccine) strain, however, much of the data comes from work with mRNA-1647. The study states:<\/p>\n

The results of a biodistribution study of mRNA-1647 support the development of mRNA-1273.<\/p>\n

<\/p>\n

***<\/p>\n

The biodistribution of mRNA-1647 was evaluated in a non-Good Laboratory Practice (GLP), single-dose, intramuscular (IM) injection study in Sprague Dawley rats\u2026. mRNAs that are within an LNP of the same composition (e.g., mRNA-1273 and mRNA-1647) are expected to distribute similarly.<\/p>\n

The \u201cSummary\u201d\u00a0indicates<\/span><\/a>:<\/p>\n